Valerenic Acids

Compound Class	Sesquiterpenic acids — the standardisation markers of Valeriana officinalis root
Representative Members	Valerenic acid, acetoxyvalerenic acid, hydroxyvalerenic acid
Botanical Source	Valeriana officinalis (valerian). Distinct from V. wallichii / V. jatamansi (Indian valerian; tagara)
Plant Part(s)	Root and rhizome
Typical Standardisation	Valerenic acids by HPLC; 0.8% is the pharmacopoeial benchmark, 1% also commercial
Primary Applications	Sleep and relaxation formulation; anxiolytic positioning
Claim Strength (Overview)	Moderate for GABA-A mechanism (well characterised); Emerging and heterogeneous for clinical sleep outcomes
Buy from Herbuno	Valerenic Acids 1% Powder (Valerian Extract) | Standardized Valeriana officinalis → Valerenic Acids 0.8% Powder (Valerian Extract) | Standardized Valeriana officinalis →

Name origin: Valerenic acid is named for the source genus Valeriana, generally traced to the Latin valere, to be strong or well. Note the plural in this monograph’s title: the pharmacopoeial marker is not one molecule but a small family of sesquiterpenic acids — valerenic acid itself plus its acetoxy and hydroxy derivatives — which is why commercial specifications read "valerenic acids." A critical disambiguation: valerenic acid is not isovaleric acid, a short-chain fatty acid responsible for valerian’s notoriously unpleasant odour and an entirely different compound with a distinct clinical association. Traditional use: Valerian has been used in European herbal medicine since Greco-Roman antiquity, with Dioscorides and Galen citing it, and has been employed continuously for restlessness, nervous tension, and difficulty sleeping — one of the most stable and unambiguous traditional indications in the Western materia medica. In Ayurveda, the related but distinct species Valeriana wallichii is used as tagara, and the two should not be conflated. Research trajectory: Valerian’s mechanism was genuinely unknown until relatively recently, which is unusual for so widely used a herb. The decisive work came from electrophysiology in the mid-2000s, establishing valerenic acid as a positive allosteric modulator of GABA-A receptors acting at the β2/β3 subunits — a site distinct from the benzodiazepine binding pocket. That mechanistic clarity has not, however, been matched by clean clinical results. Commercial source: Valeriana officinalis root and rhizome extract standardized to valerenic acid content; 0.8% is the pharmacopoeial benchmark.

---

Evidence for Valerenic Acids Applications

The mechanism is the strongest part of this compound’s case and is well established. Work using Xenopus oocyte electrophysiology demonstrated that valerenic acid acts as a positive allosteric modulator of GABA-A receptors through the β2 and β3 subunits — a binding site distinct from the benzodiazepine pocket and hence unlikely to produce the classic benzodiazepine liabilities — and separate work established that the extent of GABA-A receptor modulation by valerian extracts is directly related to the valerenic acid content of the preparation (Shi 2014). That the effect tracks the marker compound is exactly what a formulator wants to hear about a standardisation marker, and it is not always the case in this index. Claim strength: Moderate.

Importantly, the three sesquiterpenic acids in the "valerenic acids" specification are not equivalent, and this is a genuine and under-appreciated formulation point. Derivatives of valerenic acid — acetoxyvalerenic acid and hydroxyvalerenic acid — do not allosterically modulate GABA-A receptors, but they bind to the identical binding sites; when valerian extract was fractionated, the fractions with high valerenic acid and low acetoxyvalerenic acid demonstrated the most pronounced allosteric action (Becker 2014). The implication is uncomfortable for the standard specification: acetoxyvalerenic acid may act as a competitive antagonist at the same site, meaning a summed "valerenic acids 0.8%" figure could conceal an unfavourable ratio. Claim strength: Moderate.

A second compositional matter that formulators frequently miss: Valeriana officinalis root contains three pharmacologically distinct constituent classes — the sesquiterpenic acids documented here; the iridoid valepotriates (valtrate, isovaltrate, acevaltrate), which are unstable and largely decompose in aqueous preparations; and flavonoids including linarin and hesperidin. The valepotriates have historically raised cytotoxicity and mutagenicity concerns in vitro, and their instability means that an aqueous extract and an ethanolic extract of the same root are materially different products with different constituent and safety profiles. Claim strength: Moderate.

The clinical sleep evidence is where honesty is required, because it does not match the mechanistic elegance. Systematic reviews and meta-analyses of valerian for sleep have consistently reported high methodological heterogeneity, variable extract preparations, and inconsistent outcomes, with subjective sleep-quality improvements more commonly reported than objective polysomnographic changes. The kindest accurate summary is that the mechanism is real and the clinical effect is modest, inconsistent, and heavily dependent on preparation. Formulators should not overstate this. Claim strength: Emerging.

A species caution with real commercial consequence: Valeriana officinalis and Valeriana wallichii (Indian valerian, tagara, sometimes classified as V. jatamansi) are different species with different chemistry — valerenic acid content is highest in V. officinalis, present only in traces or absent in several other Valeriana species. A "valerian extract" sourced from V. wallichii may contain negligible valerenic acid and therefore cannot deliver the GABA-A mechanism documented above. Species must be named on the specification. Claim strength: High (compositional fact).

---

Dosage & Formulator Specification

Herbuno carries Valeriana officinalis root extract standardized to 1% and 0.8% valerenic acids by HPLC, alongside unstandardized valerian root extract and, separately, Indian valerian (Valeriana wallichii) extract. The two species are chemically distinct and must not be treated as interchangeable: the valerenic-acid mechanism belongs to V. officinalis, and V. wallichii should not be substituted into a formulation resting on valerenic acid content.

Clinical trial dosing has commonly used valerian root extract in the range of roughly 300–600 mg taken 30–120 minutes before bed, though preparations across the trial literature vary so widely in extraction solvent and standardisation that dose comparison between studies is genuinely difficult. Formulators should size against the assayed valerenic acid content rather than extract weight and should note that some trials report benefit emerging only after two to four weeks of continuous use rather than acutely — a pattern worth reflecting in label guidance rather than promising same-night results.

Analytical verification should specify valerenic acids by HPLC with valerenic acid and acetoxyvalerenic acid reported separately, not summed — this is more consequential here than for most compound classes, given evidence that acetoxyvalerenic acid binds the same GABA-A site without activating it and that high-valerenic/low-acetoxyvalerenic fractions showed the strongest activity. Extraction solvent should be documented, since valepotriate content and stability differ markedly between aqueous and ethanolic preparations. Species (V. officinalis) must be named.

Valerian is generally well tolerated, with headache, dizziness, gastrointestinal upset, and paradoxical excitation in a minority being the most commonly reported effects. Three cautions warrant statement. Because valerenic acid modulates GABA-A receptors, additive sedation with alcohol, benzodiazepines, barbiturates, and other CNS depressants is mechanistically plausible and warrants clear label disclosure, as does caution regarding driving and operating machinery. The valepotriates raise in-vitro cytotoxicity concerns and their content should be understood for the specific preparation. Finally, the characteristic and powerful odour of valerian root — attributable to isovaleric acid, a distinct compound from valerenic acid — is a genuine formulation and packaging constraint rather than a quality defect.

---

Frequently Asked Questions — Valerenic Acids

How does valerenic acid work?
It is a positive allosteric modulator of GABA-A receptors, acting at the beta-2 and beta-3 subunits — a binding site distinct from the benzodiazepine pocket, which is why it is unlikely to produce classic benzodiazepine liabilities. Usefully, the extent of GABA-A modulation by valerian extracts tracks directly with their valerenic acid content.

Are all three "valerenic acids" equally active?
No, and this is an under-appreciated problem with the standard specification. Acetoxyvalerenic acid and hydroxyvalerenic acid do not allosterically modulate GABA-A receptors, but they bind the same sites — potentially acting as competitive antagonists. Fractions high in valerenic acid and low in acetoxyvalerenic acid showed the strongest activity, so a summed figure can conceal an unfavourable ratio.

Is valerenic acid the same as isovaleric acid?
No — and the distinction matters. Isovaleric acid is a short-chain fatty acid responsible for valerian's notoriously unpleasant odour, and is an entirely different compound with a distinct clinical association. Valerenic acid is a sesquiterpenic acid and is the pharmacologically relevant GABA-A modulator.

Does valerian actually improve sleep?
The honest answer is: modestly, inconsistently, and depending heavily on preparation. The GABA-A mechanism is well established, but systematic reviews report high heterogeneity, variable extracts, and inconsistent outcomes, with subjective sleep-quality improvements more common than objective polysomnographic changes. The mechanism is stronger than the clinical evidence.

Related compounds: Apigenin, Hesperidin, Magnolol, Bacoside A

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery